Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ASPH | Q12797 | 2/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425000 | 0.86 | KMO (0.55) | KMOKDM4EASPHKDM8P4HTM | |
| Hydrochloric Acid SCHEMBL11809182 | 0.84 | KMO (0.40) | KMOKDM4EALOX15STAT3GRM4 | |
| SCHEMBL3408002 | 0.84 | MAPK1 (0.46) | KDM4EALOX15STAT3GRM4MAPK1 | |
| SCHEMBL18009392 | 0.83 | GPR35 (0.49) | KMOKDM4EASPHKDM8P4HTM | |
| SCHEMBL29368707 | 0.83 | GPR35 (0.49) | KMOKDM4EASPHKDM8P4HTM | |
| SCHEMBL31224184 | 0.81 | ALDH1A1 (0.49) | KDM4EALOX15STAT3GRM4 | |
| SCHEMBL24387194 | 0.80 | KMO (0.38) | KMOALOX15STAT3GRM4MAPK1 | |
| SCHEMBL29723873 | 0.80 | KMO (0.38) | KMOALOX15STAT3GRM4MAPK1 | |
| SCHEMBL7343126 | 0.80 | PTGS2 (0.46) | KMOKDM4EASPHKDM8P4HTM | |
| SCHEMBL9318874 | 0.80 | KDM4E (0.55) | KMOKDM4EASPHKDM8P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133529-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| WO-2020212351-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | WO | disclosed |
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | KMO 3025/4885KDM4E 2267/4885ASPH 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.